ALB and neoplasm: However, although albumin nanomaterials have excellent biocompatibility, nontoxicity, and nonimmunogenicity, they still have shortcomings in drug delivery: 1) they have a rapid degradation rate in vivo and are easily removed from the blood circulation; 2) they may react with proteins in the blood, thus decreasing uptake of nanomaterials by tumor cells149; and 3) because of their inherent structural properties, they may be unstable in the body’s environment, which contains various enzymes and protein complexes150.